You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
One project aims to collect patients' genomic and molecular information in a database, and another aims to tailor treatments based on patients' molecular profiles.
NRG1 gene fusions, found most commonly in lung and pancreatic cancer, are generating interest among drugmakers as a new precision medicine indication.
The company, which uses fruit fly "avatars" to screen drugs, will be collaborating with London IVD Co-operative and Genomics England to test their technology in GI cancer patients.
Of the eight patients who received drugs recommended by the tumor board based on data from the drug sensitivity assay, 75 percent responded.
Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.
Investigators saw responses in one colorectal cancer and one breast cancer patient and are now studying differences between responders and non-responders.
The drug, which is designed to restore normal functioning of p53, has allowed a promising proportion of TP53-mutated MDS patients to receive stem cell transplants in early trials.
The company raised $74.5 million in a series B financing round last December, with which it hopes to study its RAF inhibitor in various cancers with non-V600 BRAF mutations.
Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would benefit from treatment.
Glioma patients experienced tumors shrinkage, and some AML patients had a complete remission that allowed them to proceed to curative treatment.